ArticleFrontiers in oncology2026
UBTD1: a prognostic and immune biomarker validated in thyroid cancer and pan-cancer analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ubiquitin domain containing 1 (UBTD1), a molecule intimately associated with tumorigenesis and progression, is seen as a possible cancer therapy target. However, its diagnostic value, prognostic significance, and immunomodulatory functions of UBTD1 across cancers and in thyroid carcinoma have not yet been fully elucidated. Methods: Based on TCGA and other public database resources, this research carried out an extensive examination of the expression levels, prognostic potential, diagnostic value, epigenetic modifications, methylation status, immune significance, and pathway regulation of UBTD1, to explore its biological function in diverse malignant tumors. In addition, through Results: The study indicates that the overexpression of UBTD1 is prevalent in many cancers and correlates with poor prognosis. UBTD1 is effective to a moderate or strong degree in identifying cancerous tissues compared to healthy ones, and it serves as an independent prognostic factor in ACC, LIHC, READ, and THCA patients. UBTD1 mutations are prevalent across various malignancies and correlate with patient prognosis. In the majority of malignancies, UBTD1 expression is positively associated with m6A methylation, showing increased methylation in its promoter region. Moreover, experiments demonstrated that UBTD1 overexpression reduces THCA cell proliferation, invasion, and migration, whereas its under expression exhibited the opposite biological effects. Conclusion: UBTD1 can be used as a biomarker of important clinical value in pan-cancer. Concurrently, this research clarified the expression and role of UBTD1 in THCA. These findings open new avenues for developing tumor treatments targeting UBTD1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.